Masimo Corporation
MASIHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeMasimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. The $9.36B market capitalization puts MASI squarely in mid-cap range for its industry. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin.
Market Cap
$9.36B
Beta
1.13
P/E (TTM)
44.24
P/E (Fwd)
27.07
EPS (TTM)
$4.04
EPS (Fwd)
$6.60
ROE
25.0%
ROA
10.2%
Cash
$124.6M
Total Debt
$485.9M
Free CF
$327.9M
52W Change
9.7%
Annual Financials
Cash vs Debt
Masimo Corporation carries $485.9M in total debt against $124.6M in cash reserves — debt is roughly 3.9x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $327.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 25.0%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.2% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $2.04B to $1.53B.
As with any equity investment, MASI carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Masimo Corporation's trajectory.